CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 05
COPD AOP-I: quantitative modeling of in vitro data using an adverse outcome pathway for the assessment of decreased lung function risk in humans
Philip Morris International R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
Adverse outcome pathways (AOPs) organize mechanistic knowledge based on empirical evidence into a sequence of cell, tissue, and organ level events that lead to an adverse outcome (AO) in humans. An AOP initiates from the interaction of a stressor...